Objective: To determine the strategy most cost-effective between Quinagolide, Bromocriptine and Cabergoline in patients with Hyperprolactinaemia respect to the tumour percentage reduction. Methods: A cost-effectiveness analyses was made, the efficacy measures were obtained from a meta-analysis of clinical trials of patients with hyperprolactinaemia who were treated with some of the alternatives of the study. A microcosting was performed through a pickup data instrument that was validated previously, the information was validated with a Mexican panel experts. The perspective was from Mexican Institute of Social Security. The parameters obtained were introduced to the model (decision tree) in order to obtain the total cost average by a Monte Carlo microsimulation with 100,000 iterations until was obtained a mistake less than 3%. The variables used in the analyses were the proportion of percentage reduction in tumour mass with respect to the baseline, with the information obtained was performed a Cost-effectiveness analyses and probabilistic sensitivity analyses. Results: The higher cost of the treatment was with Bromocriptine (USD$3687) and the cheaper alternative was Quinagolide (USD$3347). Quinagolide was the most effective option (80%) compared with Bromocriptine. The cost per unit decreased in the percentage of tumour is smaller with Quinagolide (USD$4184 ), while Bromocriptine and Cabergoline have a higher cost (USD$6145 and USD$5243 respectively). The incremental analyses show that Quinagolide was dominant. Bromocriptine and Cabergoline are more expensive and less effective (dominated). The sensitivity analyses of probabilistic type showed that the Health Net Benefits, Monetary Net Benefits and the Acceptability curves were favourable for Quinagolide independently the willingness to pay. Conclusion: Quinagolide is the dominant option in patients with Hyperprolactinaemia. Quinagolide gives more Health Net Benefits and Monetary Net Benefits that Bromocriptine and Cabergoline independently the willingness to pay.